GoodRx and WEGOVY

What the page showed

Read on 12 September 2026, the discount service listed WEGOVY in two tables, one for tablets and one for cartons of four pens, each with a retail price beside the price it offers.²

Hold that column of prices next to what the manufacturer publishes on its own page, read the day before: $149 a month for 1.5 mg tablets, $199 for 4 mg, $299 for 9 mg and 25 mg, $199 a month for a new self-paying patient’s first two pen fills, then $349, and $399 for the 7.2 mg pen. They are the same numbers. The WEGOVY price page and the pill page have them with the footnotes attached.¹

So what is the card doing

Not negotiating this one. On a drug where the maker runs its own self-pay program, the discount service is showing you that program’s price and routing you to it. That is worth knowing before you assume there is a better number somewhere: for WEGOVY in September 2026, the floor published by the maker and the floor published by the discount service are the same floor.

The page says as much in its own FAQ, in the row about how much you can save:

Those are the manufacturer’s terms word for word, cap included. The $25 is the maker’s savings offer and needs commercial insurance; the $100 cap is what decides whether you get near $25 or not, and that is set out on the price page.¹

The two pages do not agree on the deadline

Here is the part worth checking before you rely on either. The discount page puts the introductory pen price behind a date that has already passed:

The manufacturer’s own page, read on 11 September 2026, describes the same offer as running for two monthly fills through 31 December 2026. One of those two pages is behind, and the one with the drug’s name on it is the one to ring about. Both dates are printed here with the day each page was read, because that is the only way a reader can tell which is stale next month.^2,1

Two other things on that page

It states that there is currently no generic alternative to WEGOVY. That is right, and the fuller answer is on the generic page: FDA’s records hold one abbreviated application for semaglutide, tentatively approved in April 2026 and not marketed.

It also says WEGOVY is covered by most Medicare and insurance plans. This site does not publish a figure of that shape, for the reason it gives everywhere else: it would be a claim about every plan in the country, and no census supports one. What coverage turns on, plan by plan, is on the WEGOVY coverage page. The Wegovy cost-help guide separates savings routes by the eligibility question each one asks.

Questions